BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24819900)

  • 21. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease.
    Singh JP; Kulik A; Levin R; Ellinor PT; Ruskin J; Avorn J; Choudhry NK
    Europace; 2012 Sep; 14(9):1287-93. PubMed ID: 22539600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study.
    Liu J; Masoudi FA; Spertus JA; Wang Q; Murugiah K; Spatz ES; Li J; Li X; Ross JS; Krumholz HM; Jiang L;
    J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25713293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
    Steely AM; Callas PW; Bertges DJ;
    J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
    Alba MA; García-Martínez A; Prieto-González S; Espígol-Frigolé G; Butjosa M; Tavera-Bahillo I; Rodríguez-Pintó I; Hernández-Rodríguez J; Cid MC
    Semin Arthritis Rheum; 2014 Jun; 43(6):772-7. PubMed ID: 24315461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction.
    Parashar A; Agarwal S; Krishnaswamy A; Garg A; Poddar KL; Sud K; Ellis S; Tuzcu EM; Kapadia SR
    Am J Cardiol; 2015 Aug; 116(4):508-14. PubMed ID: 26081065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.
    Sorbets E; Labreuche J; Simon T; Delorme L; Danchin N; Amarenco P; Goto S; Meune C; Eagle KA; Bhatt DL; Steg PG
    Eur Heart J; 2014 Jul; 35(26):1760-8. PubMed ID: 24616336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension.
    Her AY; Choi BG; Rha SW; Kim YH; Choi CU; Jeong MH
    PLoS One; 2020; 15(11):e0242314. PubMed ID: 33253206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effect of angiotensin converting enzyme inhibitor versus angiotensin ii type i receptor blocker in acute myocardial infarction with non-obstructive coronary arteries; from the Korea Acute Myocardial Infarction Registry - National Institute of Health.
    Ahn JH; Hyun JY; Jeong MH; Kim JH; Hong YJ; Sim DS; Kim MC; Park HS; Kim DI; Hur SH; Oh SK; Ahn Y
    Cardiol J; 2021; 28(5):738-745. PubMed ID: 33001422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI Registry.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):403-414. PubMed ID: 30788675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Atherosclerosis; 2019 Oct; 289():109-117. PubMed ID: 31491742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry.
    Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH
    Int J Cardiol; 2018 Apr; 257():168-176. PubMed ID: 29506690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation.
    Thilly N; Bayat S; Alla F; Kessler M; Briançon S; Frimat L
    Clin Transplant; 2008; 22(4):439-46. PubMed ID: 18318741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
    Longenecker JC; Alfaddagh A; Zubaid M; Rashed W; Ridha M; Alenezi F; Alhamdan R; Akbar M; Bulbanat BY; Al-Suwaidi J
    Int J Cardiol; 2013 Aug; 167(4):1406-11. PubMed ID: 22578736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention.
    Ann SH; Strauss MH; Park GM; Han S; Yang Y; Kim YG; Won KB; Kim SJ; Lee SG; Cho YR; Kim DW; Park MW; Her SH; Lee SW
    Int J Cardiol; 2020 May; 306():35-41. PubMed ID: 31727411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative assessment of angiotensin II type 1 receptor blockers in the treatment of acute myocardial infarction: surmountable vs. insurmountable antagonist.
    Jeong HC; Jeong MH; Ahn Y; Chae SC; Hur SH; Hong TJ; Kim YJ; Seong IW; Chae JK; Rhew JY; Chae IH; Cho MC; Bae JH; Rha SW; Kim CJ; Choi D; Jang YS; Yoon J; Chung WS; Cho JG; Seung KB; Park SJ;
    Int J Cardiol; 2014 Jan; 170(3):291-7. PubMed ID: 24239100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of preoperative angiotensin-converting enzyme inhibitor use on clinical outcomes after cardiac surgery.
    Ouzounian M; Buth KJ; Valeeva L; Morton CC; Hassan A; Ali IS
    Ann Thorac Surg; 2012 Feb; 93(2):559-64. PubMed ID: 22269723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program.
    Bainey KR; Armstrong PW; Fonarow GC; Cannon CP; Hernandez AF; Peterson ED; Peacock WF; Laskey WK; Zhao X; Schwamm LH; Bhatt DL
    Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):227-35. PubMed ID: 24569634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
    Goyal A; Alexander JH; Hafley GE; Graham SH; Mehta RH; Mack MJ; Wolf RK; Cohn LH; Kouchoukos NT; Harrington RA; Gennevois D; Gibson CM; Califf RM; Ferguson TB; Peterson ED;
    Ann Thorac Surg; 2007 Mar; 83(3):993-1001. PubMed ID: 17307447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.
    Wu CK; Yang YH; Juang JJ; Wang YC; Tsai CT; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Medicine (Baltimore); 2015 Jan; 94(3):e424. PubMed ID: 25621694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.